Physician profile
Emily Coyle
NPI 1174158299
$4,982.77
in general payments reported to CMS, 2019-2025
20 companies · $702 in 2025
The $702 reported for 2025 was more than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $357 · 2022: $944 · 2023: $1,596 · 2024: $1,383 · 2025: $702.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,674 · Education: $7.71.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,674.12 |
| Education | $7.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,401.45 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $780.76 | 2022-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $677.57 | 2021-2025 | Caplyta |
| Alkermes, INC. | $511.86 | 2022-2025 | Aristada, Lybalvi, Aristada Initio |
| Lundbeck LLC | $302.52 | 2021-2025 | Rexulti |
| Teva Pharmaceuticals USA, INC. | $274.56 | 2021-2025 | Uzedy, Austedo Xr, Austedo |
| Vanda Pharmaceuticals INC. | $165.52 | 2022-2025 | Fanapt, Hetlioz |
| Neurocrine Biosciences, INC. | $154.48 | 2022-2025 | Ingrezza |
| Axsome Therapeutics, INC. | $113.02 | 2023-2025 | Auvelity |
| Idorsia Pharmaceuticals US INC | $108.24 | 2022-2024 | Quviviq |
| Janssen Pharmaceuticals, INC | $87.97 | 2021-2023 | Invega Sustenna |
| E.R. Squibb & Sons, L.L.C. | $80.29 | 2024-2025 | Cobenfy |
| Takeda Pharmaceuticals U.S.A., INC. | $74.49 | 2022-2024 | Trintellix |
| Bausch Health US, LLC | $52.32 | 2023-2024 | Aplenzin |
| Almatica Pharma LLC | $47.32 | 2023-2024 | Loreev Xr |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sage Therapeutics, LLC | $45.47 | 2023-2024 | |
| Sunovion Pharmaceuticals INC. | $43.96 | 2021-2022 | |
| Indivior INC. | $31.13 | 2023-2024 | Perseris |
| Novo Nordisk INC | $16.22 | 2025 | Ozempic, Rybelsus |
| Noven Therapeutics, LLC | $13.62 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Emily Coyle listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.